tbuckley/cabot-search huggingface dataset:
Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531
Authors: Michael R. Loken, Todd A. Alonzo, Laura Pardo, Robert B. Gerbing, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Patti Byron, Laura Burden, Tanya Wallas, Stella M. Davies, Franklin O. Smith, Soheil Meshinchi, Alan S. Gamis
Journal: Blood (2010)
Does a common vascular origin confer similar prognosis to malignant tumors of the liver?
Authors: Ryan T. Groeschl, Sam G Pappas, Kathleen K. Christians, Susan Tsai, Edward J Quebbeman, T. Clark Gamblin, Kiran Turaga
Journal: Journal of Clinical Oncology (2012)

186 Background: Unlike the ubiquitous hepatic hemangioma, malignant vascular tumors (MVT) of the liver are uncommon and poorly understood. We hypothesized that tumor histology is a predominant factor associated with survival in these tumors. Methods: Patients with hepatic angiosarcoma (AS), hemangioendothelioma (HE) and its epithelioid variant (EHE), or hemangiopericytoma (HP) were identified using the SEER database (1973-2007). Standardized incidence rates were calculated based on the 2000 U.S. population. Prognostic factors were studied with Cox regression modeling. Results: We included 297 patients with MVT (207 AS, 28 HE, 56 EHE, 6 HP) with an annual standardized incidence of 3 per million. Patients with AS were likely to be older at diagnosis (median 63 yrs, p = 0.001) and less likely to be female (38%, p &lt; 0.001). All tumors demonstrated metastatic potential, although EHE and AS had the highest rate of regional or distant metastases (75% each, p = 0.05, Table 1). Patients with EHE had the overall longest median survival of 75 (30-183) months (p &lt; 0.001). Surgical resection and transplant did not improve the overall survival of patients with EHE in multivariate models (p = 0.2, 0.9). Conclusions: Histology is an important factor in determining survival for patients with hepatic MVT. Patients with EHE have the longest OS even in the absence of surgical intervention, whereas patients with AS have shorter survival but appear to benefit from surgery. [Table: see text]
Defective Inhibitory Signaling in CLL B Cells and Increased Recruitment of PI3K by c-Cbl in Zap-70+ CLL.
Authors: Xin Kai, Vasant Chellappa, Jesse Moya, Kendra N. Taylor, Ephraim P. Hochberg, Philip C. Amrein, Shiv Pillai
Journal: Blood (2009)
Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States
Authors: Elizabeth K Goodman, Yimei Li, Alix E. Seif, Julie Fitzgerald, Yuan-Shung Huang, Rochelle Bagatell, Brian T. Fisher, Richard Aplenc
Journal: Blood (2014)
In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.
Authors: John A. Lust, Martha Q. Lacy, Steven R. Zeldenrust, Angela Dispenzieri, Morie A. Gertz, Philip R. Greipp, Thomas E. Witzig, Susan M. Geyer, Laurie L. Moon-Tasson, S. Vincent Rajkumar, Kathleen A. Donovan
Journal: Blood (2005)
Burden of Arrhythmia in Pregnancy
Authors: Vaibhav R. Vaidya, Shilpkumar Arora, Nileshkumar Patel, Apurva O. Badheka, Nilay Patel, Kanishk Agnihotri, Zeenia Billimoria, Mintu P. Turakhia, Paul A. Friedman, Malini Madhavan, Suraj Kapa, Peter A. Noseworthy, Yong-Mei Cha, Bernard Gersh, Samuel J. Asirvatham, Abhishek J. Deshmukh
Journal: Circulation (2017)
Adult Patients with Stable Sickle Cell Disease Prior to Treatment with the iNKT Cell Depleting Antibody NKTT120 Have Consistent and Elevated Numbers of Activated (CD69+) iNKT Cells Relative to Healthy Adult Volunteers
Authors: Rosemary Mazanet, Robert Schaub, Felix Scheuplein, Cheryl A. Eaton, Robert Mashal, Joshua J. Field
Journal: Blood (2014)
Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC).
Authors: Rahul Raj Aggarwal, Carl Formaker, Eric Jay Small, Arturo Molina, Charles J. Ryan
Journal: Journal of Clinical Oncology (2012)

4664 Background: Patients (pts) with CRPC treated with keto often experience a rise in serum adrenal androgen levels upon progression and may subsequently respond to more potent adrenal suppression with AA. In contrast, pts treated with AA do not have a rise in serum androgen levels upon progression, and thus may not respond to further androgen synthesis inhibition with keto but require other treatment modalities such as chemotherapy instead. The goal of this analysis is to report the outcomes of pts with CRPC progressing on AA subsequently treated with either keto or D. Methods: Pts with chemotherapy-naïve CRPC were treated on previously reported phase 1 and 2 trials of AA, with doses ranging from 250 to 1000 mg/day. Subsequent treatment following progression on AA was per individual investigator discretion, including treatment with either keto or D. Results: To date, following disease progression on AA, 6 and 14 pts have been subsequently treated with either keto or D respectively. Of the 14 pts treated with D, 11 (79%) had exposure to keto prior to AA. The keto- and D-treated cohorts were similar with respect to other baseline factors, including prior response to AA (4/6 (67%) pts with &gt; 50% PSA decline on AA in keto cohort; 10/14 (71%) pts in D cohort); though pts treated with D were more likely to require opioid analgesics (0 pts in keto cohort; 7 (50%) in D). For pts treated with keto, none experienced a decline in PSA, improvement in bone scan, or an objective response; all had disease progression by 12 weeks. In contrast, for pts treated with D, 10 (71%) had a decline in PSA; 6 (43%) with a &gt; 50% maximum PSA decline. Of 6 pts with measurable disease, 2 (33%) had an objective response. The median time to progression for the D cohort was 129 days (range 60 – 294). Conclusions: Although the cohort size is small, and post-AA therapy was not randomized, these data provide preliminary support for the hypothesis that CRPC progressing on AA is cross-resistant to further androgen synthesis inhibition with keto. Contrary to other reports, prior treatment with AA does not appear to decrease the likelihood of subsequent response to D, but this observation requires prospective validation.
Histiocytoses: emerging neoplasia behind inflammation
Authors: Julien Haroche, Fleur Cohen-Aubart, Barret J Rollins, Jean Donadieu, Frédéric Charlotte, Ahmed Idbaih, Augusto Vaglio, Omar Abdel-Wahab, Jean-François Emile, Zahir Amoura
Journal: The Lancet Oncology (2017)
Role of lymphotoxin-a and interleukin-17A in human prostate cancer.
Authors: Sophie Burbridge, Robert Michael Goldstein, Declan Cahill, Simon Chowdhury, John Maher
Journal: Journal of Clinical Oncology (2012)

212 Background: Infiltrating immune cells have been implicated in prostate carcinogenesis. Murine studies suggest that B-cell-derived lymphotoxin (LT)a may be a key effector in the evolution to castrate-resistant prostate cancer (CRPC) (Ammirante et al, Nature 2011). Lymphotoxin a has also been implicated in the progression of murine fibrosarcoma, where it complements interleukin (IL)-17A, to synergistically enhance NFkB signaling. This interaction may also apply to human prostate cancer since IL-17-producing T h 17 cells are abundant in these tumors. However, the role of LTα in human as distinct from murine prostate cancer remains unclear. Clinical validation is vital since murine models poorly recapitulate the behavior of prostate cancer in man. Methods: Serum levels of LTα and IL-17A were measured by ELISA in patients with benign (n=22) and malignant prostate disease (n=87). Samples were from 29 early prostate cancer patients (amenable to radical therapy), 28 with androgen-sensitive (AS) disease and 30 with CRPC. Data were not normally distributed and thus were analyzed by Mann-Whitney U test. Results: Serum LTαand IL-17A were significantly elevated in patients with both CRPC and early stage prostate cancer, compared to those with benign disease. LTαwas significantly raised in CRPC compared to AS disease. IL-17A was significantly higher in the early stage disease compared to AS prostate cancer. Conclusions: Based upon these data, we hypothesize that B-cell derived LTα synergises with T h 17 derived IL-17A from the earliest stage of primary tumor development. In support of this, blockade of LTα in prostate cancer-prone (TRAMP) mice delays primary tumor onset and inhibits metastasis. Furthermore, NSAIDs protect more strongly against lifetime risk of prostate cancer in those individuals with an LTα over-producer polymorphism. Prostate cancer preferentially metastasizes to local lymph nodes and bone – sites at which mature B-cells are plentiful. Consequently, tumor-trophic effects of LTα would become increasingly efficient with disease progression. Our data are incompatible with and thus refute the clinical relevance of a role for androgen ablation in promoting LTα-driven CRPC.
Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling.
Authors: Evdoxia Hatjiharissi, Constantine S. Mitsiades, Ciccarelli T. Bryan, Xu Lian, Cao Yang, Sophia Adamia, Xavier Leleu, Aldo Roccaro, Leukothea Ioakimidis, Zachary R. Hunter, Christopher J. Patterson, Irene Ghobrial, Steven P. Treon
Journal: Blood (2007)
Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt’s Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2 Restoration.
Authors: Roberta Zappasodi, Massimo Di Nicola, Francesca Baldan, Marilena V Iorio, Michele Magni, Elda Tagliabue, Carlo M. Croce, Carmelo Carlo-Stella, Alessandro M. Gianni
Journal: Blood (2008)
Go with the Flow
Authors: Martin H. Steinberg
Journal: New England Journal of Medicine (2017)

The complications of sickle cell disease are due to sickle vaso-occlusion and hemolytic anemia.1 This multifaceted pathogenesis is initiated by the polymerization of deoxygenated sickle hemoglobin. Polymer-induced erythrocyte injury has downstream effects that include hemolysis, leukocyte–platelet–erythrocyte–endothelial interactions, inflammation, and oxidant-induced tissue damage. Sickle vaso-occlusion is most apparent clinically as an acute painful episode (called a crisis).Fetal hemoglobin inhibits the polymerization of deoxygenated sickle hemoglobin. Persons who inherit the sickle hemoglobin gene as well as a gene that prevents the natural fetal-to-adult hemoglobin switch have approximately one third fetal hemoglobin in all their erythrocytes. They do not have either hemolytic . . .
DDEL-19PENETRATION OF HOMING PEPTIDE-FUNCTIONALIZED NANOPARTICLES TO GLIOMA SPHEROIDS IN VITRO
Authors: Kadri Toome, Anne-Mari Anton Willmore, Pille Säälik, Gary B. Braun, Ramsey Majzoub, Cyrus R. Safinya, Rolf Bjerkvig, Tambet Teesalu
Journal: Neuro-Oncology (2015)

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain malignancy.Even when subjected to multimodal treatment using surgery, chemo-and radiotherapy, the majority of GBM patients die within a year after diagnosis.Affinity targeting of anti-glioma drugs to Overall survival
Somatic Mutation Analysis of Immunoglobulin (IG) Genes in Chronic Lymphocytic Leukemia (CLL) and Comparison to Normal and Autoreactive IG Sequences Reveals CLL-Biased Patterns for Selected IG Genes.
Authors: Kostas Stamatopoulos, Chrysoula Belessi, Thanassis Andreou, Anastasia Hadzidimitriou, Niki Stavroyianni, Tanja Smilevska, Fotini Marantidou, Nikolaos Laoutaris, Achilles Anagnostopoulos, George Nikiforidis, Athanasios Fassas
Journal: Blood (2005)
Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up.
Authors: Avichai Shimoni, Avital Rand, Izhar Hardan, Noga Shem-Tov, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2008)
Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity.
Authors: Marieke Griffioen, M. Willy Honders, Edith D. van der Meijden, Roelof Willemze, J.H. Frederik Falkenburg
Journal: Blood (2008)
Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.
Authors: Katsumi Nishiya, Keiji Nogami, Kiyotaka Okada, Osamu Matsuo, Masahiro Takeyama, Kenichi Ogiwara, Ichiro Tanaka, Akira Yoshioka, Midori Shima
Journal: Blood (2007)
Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia
Authors: Heinz Gisslinger, Juergen Thiele, Bettina Gisslinger, Tiina Berg, Martin Schalling, Ashot S Harutyunyan, Jelena D. Milosevic, Klaudia Bagienski, Nicole C.C. Them, Veronika Buxhofer-Ausch, Guenther Nirnberger, Leonhard Muellauer, Robert Kralovics
Journal: Blood (2014)
Synergistic Anti-Myeloma Effects of the Lyn Kinase Inhibitor INNO-406 In Combination with Doxorubicin, Melphalan and Bortezomib
Authors: Zhi-Wei Li, Eric Sanchez, Cathy Wang, Mingjie Li, David Ramirez, Cydney Nichols, Jennifer Li, Haiming Chen, James R. Berenson
Journal: Blood (2010)
STENT COLONICO COMO PUENTE A LA CIRUGÍA EN LAS NEOPLASIAS COLORECTALES OCLUSIVAS. ¿LO ESTAMOS HACIENDO MAL?
Authors: C Dolz Abadia, A Crespi Mir, SA De La Llave, J Romero Marcos, L Lozano Salva, J Olea Martinez, P Sanchis Cortes, A Vilella Martorell, J Cifuentes Rodenas
Journal: Endoscopy (2015)

Introducción: La oclusión intestinal por CCR, se ha tratado mediante una colostomía urgente. La colocación de un stent ha demostrado ser una alternativa eficaz como puente a la cirugía. Pero, se ha apuntado que puede incrementar el riesgo de diseminación y empeorar el pronóstico
Re: Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-controlled Clinical Studies
Authors: Stephan Madersbacher
Journal: European Urology (2017)
Glucose Catabolism with Resultant Formation of Reactive Oxygen Species and Local Hypoxia Modulates the Induction and Expansion of Hematopoietic Stem Cells
Authors: James M Harris, Lauren J Harris, Michael C Dovey, Claire C Cutting, Barry H Paw, Matthew G Vander Heiden, Wolfram Goessling, Trista E North
Journal: Blood (2010)
ATNT-03FIRST IN HUMAN STUDY OF RHENIUM NANOLIPOSOMES FOR INTRATUMORAL THERAPY OF GLIOMA
Authors: John Floyd, William Phillips, Beth Goins, Ande Bao, Andrew Brenner
Journal: Neuro-Oncology (2015)

BACKGROUND: Using a special methodology for radiolabeling lipid nanoparticles with therapeutic radionuclides, we have developed 186Re-nanoliposomes (186RNL). The liposomes, not unlike the membranes of human cells, are composed of a bilayer of distearoylphosphatidylcholine and cholesterol, and confer drug delivery control on beta emitting 186Re. This then permits the delivery of 186Re radiation of high specific activity which is retained within the tumor. METHODS: A phase 1 dose escalation study of 186RNL in recurrent glioma utilizing a standard 3 + 3 design was undertaken to determine the maximum tolerated dose of 186RNL by convection enhanced delivery following stereotactic biopsy. 186RNL is administered by the use of the SmartFlow Flex catheter (BrainLab) by convection enhanced delivery intra-tumorally. Catheter placement is guided using iPlan Flow and the Varioguide systems (BrainLab). Following catheter placement, patients are taken to a nuclear medicine suite where direct visualization of 186RNL infusion is followed under whole body planar imaging and SPECT/CT. Repeat imaging is performed immediately following, and at 1, 5, and 8 days after administration to obtain radiation dosimetry and distribution. RESULTS: Three patients have been treated to date with 1mCi to achieve a treatment field volume of 5mL. Catheter placement for all 3 cases has closely matched the stereotactic plan based upon MRI fusion with SPECT/CT. No treatment related adverse effects have been observed to date despite absorbed doses up to 140Gy (37 MBq). For patient 01, loco-regional retention was 76.8% of administered radioactivity on average from time 0 to 72 hours. During the 120 hour monitoring period, there was a trend toward slow loco-regional dispersion of radioactivity, which is indicated by larger extended radioactivity distribution volumes increasing from 19mL at 40 minutes to 31mL at 120 hours. CONCLUSION: Initial results of 186RNL delivery by CED are promising and the study will continue until an MTD is reached.
CCG suspends non-urgent surgery amid cash crisis
Authors: Gareth Iacobucci
Journal: BMJ (2017)

A cash starved clinical commissioning group has suspended non-urgent surgery such as hip and knee replacements until April 2017 in a bid to make financial savings.

West Kent Clinical Commissioning Group (CCG) implemented the measures from December 2016 onwards in an attempt to generate savings of £3.2m (€3.7m; $4m) by the end of this financial year.

The move was criticised by the Royal College of Surgeons (RCS), which said that the length of the suspension made it the most severe example yet of NHS rationing, and warned that it could harm patients.

The plans were disclosed in recent CCG board papers1 which explain that the policy had been enacted …
Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring
Authors: Clémence Loiseau, Francois Lemonnier, Odile Randrianarivelo, Raphael Itzykson, Marie Hélène Becquemin, Stephanie Nguyen Quoc, Madalina Uzunov, Emilie Catherinot, Elisabeth Rivaud, Laurent Sutton, Jean-Paul Vernant, Louis Jean Couderc, Nathalie Dhedin
Journal: Blood (2015)
Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
Authors: D. Lakdawalla, J. Penrod, R. Maclean, J. S. Humphrey, S. Seabury
Journal: Journal of Clinical Oncology (2011)

405 Background: Traditional CE approaches often produce results that appear to be at odds with patients' (pts) behavior. Patients with terminal disease often value gains in survival much more highly than is suggested by standard CE estimates. In the context of metastatic cancer, CE classifies as cost-ineffective many therapies that pts appear to value highly. This study assesses whether CE analyses conflict with estimates of pt value for mCRC therapy. We infer pt value from the willingness to pay (WTP) of cancer pts for therapy out-of-pocket (OOP), and compare these estimates to the value implied by traditional CE. In contrast to traditional CE approaches, this study uses real-world data on pts' own WTP for therapy OOP. Methods: Revealed preference analysis is performed on retrospective claims data, including the pt OOP spending component, to infer the value metastatic cancer pts (N=13,938) place on 29 different therapies for CRC, breast, lung or head and neck cancer. The primary outcome measure is the average value placed by pts on therapy. Secondary outcomes are: utilization of therapy, total expenditures on cancer drugs, and the price elasticity of demand for therapy. Results: Utilization of therapy displays a negative but inelastic relationship with OOP spending on drugs (the estimated price elasticity is -0.007, with p&lt;0.01). The estimated annual WTP OOP for treatment of mCRC specifically was $207,555, approximately 19 times the average annual cost of therapy ($10,775). Approximately 99% of mCRC pts value the therapy more than the cost. The analysis implies that the average mCRC pt values a statistical life year at approximately $282,000. In comparison, traditional CE analyses employed by regulators assign much lower values for a statistical life-year; for example, the UK's NICE uses a threshold of &lt;$50,000 per year. Conclusions: Traditional economic valuations of medical treatment perform poorly in the terminal care setting, because they fail to recognize that pts place higher value on care provided at the end of life. As a result, these methods vastly understate the CE of treatment for mCRC and other terminal diseases. Use of pts' own OOP spending behavior appears to produce different conclusions for the value of therapy. [Table: see text]
Studies on cognitively driven attention suggest that late vision is cognitively penetrated, whereas early vision is not
Authors: Athanassios Raftopoulos
Journal: Behavioral and Brain Sciences (2016)

Abstract Firestone &amp; Scholl (F&amp;S) examine, among other possible cognitive influences on perception, the effects of peripheral attention and conclude that these effects do not entail cognition directly affecting perception. Studies in neuroscience with other forms of attention, however, suggest that a stage of vision, namely late vision, is cognitively penetrated mainly through the effects of cognitively driven spatial and object-centered attention.
Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).
Authors: Maurizio Zangari, Bart Barlogie, Klaus Hollmig, Athanasios Fassas, Erik Rasmussen, Raymond Thertulien, Giampaolo Talamo, Choon-Kee Lee, Guido Tricot
Journal: Blood (2004)
Facteurs prédictifs endoscopiques d’infiltration profonde des nappes villeuses colo-rectales
Journal: Endoscopy (2016)

Les nappes villeuses colorectales (ou LST pour laterally spreading tumors) posent toujours le même problème à l’endoscopiste: une résection endoscopique, de préférence en un seul fragment, est-elle adéquate ou dois-je confier le malade à un chirurgien? Et cette question sous-tend la suivante: puis-je prédire endoscopiquement l’extension en profondeur de la lésion et donc savoir à l’avance si un traitement endoscopique sera carcinologiquement satisfaisant du point de vue du risque ganglionnaire? En d’autres termes, la lésion dépasse-t-elle les 1000 μm d’infiltration sous-muqueuse?